This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone

This study has been terminated.
(Recruitment problems (not enough patients were found who met eligibility criteria))
University Hospital, Geneva
University of Lausanne Hospitals
Information provided by:
University Hospital Inselspital, Berne Identifier:
First received: March 7, 2011
Last updated: April 17, 2013
Last verified: April 2013
Accumulation of salt and water in patients with liver disease (so called liver cirrhosis) is possibly related to the increased effect of steroid hormones on salt reabsorption in the kidney. By reducing overall steroid production with the dexamethasone the accumulation of salt and water could be prevented.

Condition Intervention Phase
Liver Cirrhosis Drug: Dexamethasone Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Randomized Double Blind Placebo Controlled Intervention Study of the Effect of Dexamethasone on the Sodium Retention in Patients With Liver Cirrhosis

Resource links provided by NLM:

Further study details as provided by University Hospital Inselspital, Berne:

Primary Outcome Measures:
  • Daily sodium excretion of sodium in the urine [ Time Frame: 4 days ]

Secondary Outcome Measures:
  • Daily potassium excretion [ Time Frame: 4 days ]
  • weight reduction [ Time Frame: 4 days ]
  • Reduction of doses of diuretics [ Time Frame: 4 days ]
  • Reduction of ascites [ Time Frame: 4 days ]
  • Reduction of cortisol excretion in the urine [ Time Frame: 4 days ]
  • Reduction of cortisol levels in the urine [ Time Frame: 4 days ]

Enrollment: 2
Study Start Date: February 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dexamethasone Drug: Dexamethasone
Daily administration of 2 mg of dexamethasone for 4 days
Placebo Comparator: Placebo Drug: Placebo
Daily administration of 2 mg of placebo for 4 days


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with established liver cirrhosis (biopsy or biochemically)
  • hepatorenal syndrome type 1 or 2 (with a serum creatinin >175 umol/l)
  • age between 18 and 75
  • no bacterial infection
  • no cardiovascular or extrahepatic disease (end of life)
  • no structural kidney disease
  • no hepatocellular carcinoma

Exclusion Criteria:

  • age under 15 or over 75
  • treatment with corticosteroids (dexamethasone included)
  • bacterial infection
  • cardiovascular or extrahepatic disease (end of life)
  • structural kidney disease (indicated by hematuria, proteinuria)
  • hepatocellular carcinoma
  • mental disability
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01311167

University Hospital Lausanne
Lausanne, Vaud, Switzerland
University Hospital Inselspital
Bern, Switzerland, 3010
University Hospital Geneva
Geneva, Switzerland
Sponsors and Collaborators
University Hospital Inselspital, Berne
University Hospital, Geneva
University of Lausanne Hospitals
  More Information

Responsible Party: National Center of Competence Kidney.CH, Swiss National Foundation Identifier: NCT01311167     History of Changes
Other Study ID Numbers: Dexa_Cirr_2011
Study First Received: March 7, 2011
Last Updated: April 17, 2013

Keywords provided by University Hospital Inselspital, Berne:

Additional relevant MeSH terms:
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Water-Electrolyte Imbalance
Metabolic Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017